Myriad Genetics at NSGC 2025: Collaborate and innovate together

At Myriad, we recognize the critical role genetic counselors play in patient care, which is why the National Society of Genetic Counselors (NSGC) Conference is so significant. This event provides an unparalleled opportunity for collaboration, allowing us to engage directly with you—our valued partners. 

By visiting booth #317, you can explore the latest research, innovations, and support services available from Myriad.  

Accurate genetic and genomic testing with best-in-class support1-4

Myriad offers a portfolio of genetic and genomic tests that deliver personalized insights and help patients and healthcare providers detect health risks, tailor treatments, and prevent disease with precision.

Explore products in our cancer care continuum

Discover the latest enhancements in prenatal screening

Your fellow genetic counselors are at your service

Genetic specialists like you emotionally support and guide patients through some of life’s most important journeys—no matter how high your caseloads mount.

That’s why Myriad is grateful to have one of the largest teams of board-certified genetic counselors in the nation. You can customize their services to help extend your circle of care, with:

Discover all the ways we can help you meet the rapidly rising demand for your expert guidance.

Services that complement your practice

Our comprehensive support services help reduce administrative burdens, increase confidence, and accelerate clinical action, at no extra cost for you and your patients.5

Genetic testing with Myriad provides you access to our board-certified genetic counselors for pre- and post-test patient support in 200+ languages, 5 days a week at no extra cost. We’re here to complement your practice workflow as you increase patient caseloads.

See how our team can help

  • Free up your time with seamless, efficient workflows

  • Expand your reach with Patient Education on demand

Poster Presentations:

MyRisk® Hereditary Cancer Test

Leveraging a Longitudinal Genomics Platform to Recontact Patients Eligible for Hereditary Cancer Genetic Testing

Date: Saturday, November 8, 5:00PM

Product: MyRisk

Presenter: Kaylee Henson, MS, CGC

RNA Analysis from Residual Blood Aids the Interpretation of VUS Identified in Individuals Undergoing Hereditary Cancer Genetic Testing

Date: Friday, November 7, 5:15PM

Product: MyRisk

Presenter: Paola Nix, Phd, HCLD (ABB)

Prequel® Prenatal Screen

Fetal Fraction Amplification Yields Sufficient Fetal Fraction to Enable cfDNA Screening with a Low Screen-Failure Rate Between 8-10 Weeks Gestation

Date: Friday, November 7, 5:15PM

Product: Prequel

Presenter: Ronit Lebor, MS, CGC

Provider & Patient Uptake of Prenatal cfDNA Screening at an Earlier Gestational Age

Date: Friday, November 7, 5:15PM

Product: Prequel

Presenter: Lauren Eisemann, MS, CGC

Prenatal Cell-Free DNA Screening Helps Uncover Maternal Colorectal Cancer: A Case Study

Date: Friday, November 7, 5:15PM

Product: Prequel

Presenter: Meghan Krieger, MS, CGC

Foresight® Carrier Screen

High-Throughput, Automated Detection of FXN Repeat Expansions Using Repeat Primed PCR Followed by Capillary Electrophoresis

Date: Friday, November 7, 5:15PM

Product: Foresight

Presenter: Jhett Bordwell, MS, PhD

FirstGene Multiple Prenatal Screen

From Concept to Care: The Evolution of a Genetic Screening Report through Clinical and Design Collaboration

Date: Friday, November 7, 5:15PM

Product: FirstGene

Presenter: Summer Pierson, MS, CGC

Myriad Collaborative Research Registry

The Spectrum of Germline Hereditary Cancer Mutations Within a Laboratory-Based Research Registry

Date: Friday, November 7, 5:15PM

Product: MCRR

Presenter: Damini Morah, MS, CGC

EXTERNALLY DRIVEN - Comparison of Cancer Types Associated with ATM and CHEK2 Within a Hospital System and National Registry

Date: TBD

Product: MCRR

Presenter: McCall Larson

Professional Development

Shaping the Future: Evolving a Field-Based Laboratory Rotation to Meet the Needs of Genetic Counseling Students

Date: Friday, November 7, 5:15PM

Presenter: Sarah Pass, MMSc, CGC

Genetic Counseling Student Interest in GC Roles in an Industry Rotation Setting

Date: Friday, November 7, 5:15PM

Presenter: Heather Bagley, MS, CGC

Professional Development for Seasoned Genetic Counselors: Moving from Clinical Expertise to Leadership Excellence

Date: Saturday, November 8, 5:00PM

Presenter: Susan Manley, LCGC, MBA

Get customized patient education and seamless support from fellow genetic counselors, so you can help even more patients—all at no extra cost

Connect with us

References:
  1. Judkins, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer 2015. DOI: 10.1186/s12885-015-1224-y
  2. Gradishar W, Johnson K, Brown K, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803.
  3. Hogan GJ, Vysotskaia VS, Beauchamp KA, et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clin Chem.2018;64(7):1063-1073. doi:10.1373/clinchem.2018.286823
  4. Hancock S, Ben-Shachar R, Adusei C, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol.2020;56(3):422-430. doi:10.1002/uog.21904.
  5. Richard N. Waldman, MD, Mark S. DeFrancesco, MD, John P. Feltz, MD, Daniel S. Welling, MD, Wade A. Neiman, MD, Melissa M. Pearlstone, MD, Christine A. Marraccini, MD, DanaKaranik, RN, Elaine Mielcarski, CNM, Logan Schneider, MS, Lauren Lenz, MS, Edith C. Smith, DNP, Katherine Johansen Taber, PhD, and Royce T. Adkins, MD, FACS, Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing. Obstetrics & Gynecology 145(2):p 177-185, February 2025.